231 related articles for article (PubMed ID: 24660228)
1. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
[TBL] [Abstract][Full Text] [Related]
2. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
[TBL] [Abstract][Full Text] [Related]
3. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
[TBL] [Abstract][Full Text] [Related]
4. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
Aznar MC; Maraldo MV; Schut DA; Lundemann M; Brodin NP; Vogelius IR; Berthelsen AK; Specht L; Petersen PM
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):169-74. PubMed ID: 25754634
[TBL] [Abstract][Full Text] [Related]
5. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
Weber DC; Peguret N; Dipasquale G; Cozzi L
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
[TBL] [Abstract][Full Text] [Related]
6. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
7. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
8. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
[TBL] [Abstract][Full Text] [Related]
9. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma.
Jørgensen AY; Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Rosenschöld PM; Petersen PM; Specht L
Acta Oncol; 2013 Oct; 52(7):1559-65. PubMed ID: 24047340
[TBL] [Abstract][Full Text] [Related]
10. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck Af Rosenschöld P; Petersen PM; Specht L
Radiother Oncol; 2014 Mar; 110(3):441-7. PubMed ID: 24188865
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
12. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
[TBL] [Abstract][Full Text] [Related]
13. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
14. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
[TBL] [Abstract][Full Text] [Related]
15. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease.
Lautenschlaeger S; Iancu G; Flatten V; Baumann K; Thiemer M; Dumke C; Zink K; Hauswald H; Vordermark D; Mauz-Körholz C; Engenhart-Cabillic R; Eberle F
Radiat Oncol; 2019 Sep; 14(1):157. PubMed ID: 31477141
[TBL] [Abstract][Full Text] [Related]
16. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
Mazonakis M; Lyraraki E; Damilakis J
Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
[TBL] [Abstract][Full Text] [Related]
17. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma.
Maraldo MV; Brodin NP; Vogelius IR; Aznar MC; Munck Af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1232-7. PubMed ID: 22270170
[TBL] [Abstract][Full Text] [Related]
18. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
19. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
Hodgson DC; Koh ES; Tran TH; Heydarian M; Tsang R; Pintilie M; Xu T; Huang L; Sachs RK; Brenner DJ
Cancer; 2007 Dec; 110(11):2576-86. PubMed ID: 17941006
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
